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SUMMARY – Recent developments in the diagnosis and treatment of chronic lymphocytic leu-
kemia (B-CLL) have led to change of approach in clinical practice. New treatments have been 
 approved based on the results of randomized multicenter trials for fi rst line and for salvage therapy, 
and the results of numerous ongoing clinical trials are permanently providing new answers and further 
refi ning of therapeutic strategies. Th is is paralleled by substantial increase in understanding the  disease 
genetics due to major advances in the next generation sequencing (NGS) technology. We defi ne cur-
rent position of the Croatian Cooperative Group for Hematologic Disease on diagnosis and treat-
ment of CLL in the transition from chemo-immunotherapy paradigm into a new one that is based on 
new diagnostic stratifi cation and unprecedented therapeutic results of B-cell receptor inhibitors (BRI) 
and Bcl-2 antagonists. Th is is a rapidly evolving fi eld as a great number of ongoing clinical trials 
 constantly accumulate and provide new knowledge. We believe that novel therapy research including 
genomic diagnosis is likely to off er new options that will eventually lead to time limited therapies 
without chemotherapy and more eff ective clinical care for B-CLL based on individualized precision 
medicine.
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Introduction and defi nition
In recent years, dramatic change in therapeutic 
landscape led to unprecedented therapeutic results 
that were translated to clinical practice, and after years 
of slow to modest progress in the fi eld of B-cell chron-
ic lymphocytic leukemia (B-CLL), the American So-
ciety of Clinical Oncology (ASCO) named transfor-
mation of CLL treatment Cancer Advance of the Year 
for 20151. New treatments were approved based on the 
results of randomized multicenter trials for fi rst line 
and for salvage therapy, and the results of numerous 
ongoing clinical trials are permanently providing new 
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Table 1. Steps and aims in diagnostic process that leads to defi nition of therapeutic goal and strategy
STEPS AND AIMS BASIS FOR DECISION CRITERIA
TARGETED 
CATEGORIES 
OF CLASSIFICATION
1
Disease detection;
Patient – hematologist 
contact
•  Lymphocytosis 
(70%-80%) and/or
•  Lymph nodes/spleen 
enlargement (20%-30%)
• PE and hematology lab
2 Diagnosis and diff erential diagnosis
•  B-cell clone of typical 
B-CLL phenotype 
(in PB and/or BM 
and/or LN)
•  Other 
lymphoproliferative 
disease with 
lymphocytosis 
•  Morphology 
+ characteristic immuno-
phenoptype with 
quantifi cations
•  Diff erence in phenotype 
and/or morphology
•  CLL (73%)
•  SLL (7%)
•  MBL
•  B (15%): FL, MCL, 
MZL, PLL, HCL
•  T (5%): PLL, TLLO, 
Sezary, LGL
3 Disease extent assessment
•  Clinical and lab 
(hematology) 
assessment
• Rai,
• Binet,
• TTM 
• 0, I, II, III, IV
• A, B, C
•  Continuous parameter 
of the size and 
distribution of tumor 
mass
4 Classifi cation in prognostic groups • PFs @ dg
•  Prognostic markers (CD38 
and ZAP), FISH(4),
•  Prognostic indices,
•  Mutation status of IgHV 
genes
• Good prognosis
• Poor prognosis
5 Indications for therapy 
•  Quantitative threshold 
criteria
• Dynamic criteria
• Qualitative criteria
•  Anemia, thrombocytopenia, 
organomegaly, 
lymphocytosis
•  Trend of tumor load 
increase (DT), progressive 
cytopenias
•  Presence of symptoms
•  Early, stable, 
asymptomatic disease 
= observation only
•  Any other = indication 
for therapy
6
Immediate 
pre-treatment 
evaluation and 
comorbidity 
& general condition 
assessment
•  Clinical and laboratory 
assessment
•  Updating and completing 
work-up
• CIRS
• Fit
• Unfi t
7
Individualization 
of therapy
Th erapy aim and 
strategy defi nition
• B-CLL related factors
• Patient related factors
•  Diff erence in advancement 
and progressiveness, p53
•  General condition and 
comorbidity
Stratifi cation (2x2):
• High risk/Low risk
• Fit/Unfi t (frail)
Comment: the table shows diagnostic steps. Steps 1-4 are made in single visit. Each step is diff erent with respect to aim, decision criteria, 
and the extent of work-up. Last column describes classifi cation categories proposed. Only about 10% of patients have indication for ther-
apy at diagnosis. Others are followed-up repeatedly until the criteria for therapy are reached (step 5). Th e scope of work-up is diff erent in 
each step, pretreatment evaluation being most complete, aiming to provide all the necessary elements for patient stratifi cation and defi nition 
of therapeutic goal. Th e overall goal of diagnostic process is to enable individualization of therapy, defi nition of therapeutic aim and strat-
egy, by implementing general principles to each individual case.
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answers and further refi ning of therapeutic strategies. 
Th is is paralleled by substantial increase in under-
standing the disease genetics owing to major advances 
in the next generation sequencing (NGS) technolo-
gy2,3. All these have led to change of the until now pre-
dominant paradigm based on chemo-immunotherapy 
(CIT) to a new one4,5.
Defi nition. B-cell chronic lymphocytic leukemia 
and related disorders (monoclonal B-lymphocytosis 
(MBL) and small lymphocytic lymphoma (SLL)) are 
defi ned by the presence of clonal mature B-lympho-
cytes with typical immunophenotype in peripheral 
blood, bone marrow and lymphoid organs (WHO, iw-
CLL)6,7 representing one nosologic entity. Today, it is 
considered that these entities are diff erent manifesta-
tions of the same disease. MBL is most prevalent and 
is considered as an early stage of malignancy progress-
ing to CLL/SLL in 1%-2% of cases per year. SLL ac-
counts for less than 10% of overt malignancy, and for 
this reason B-CLL is most commonly used to repre-
sent both variants (CLL/SLL)6,8-17.
Epidemiology. B-CLL is the most common type 
of leukemia in Western countries. Th e incidence is es-
timated to more than 6 per 100,000 people annually. 
Th e median age at diagnosis is growing globally, so 
that now exceeds 70 years. It should be noted that the 
age at treatment initiation is several years older than 
the age at diagnosis, depending on the duration of ob-
servation without treatment. Th e disease is nearly 
twice as common in men18-22. Th e incidence and preva-
lence of MBL is much higher, depends on sensitivity 
of the methods used, and is estimated to involve up to 
12% of the population aged over 40 years23,24.
Diagnostic procedure
Th e diagnostic process can be conditionally divided 
into several sections (steps, phases) with respect to dif-
ferent objectives to be achieved. In Table 1, the basis 
for decision is specifi ed, along with the main criteria 
for classifi cation and the possible categories to which 
the classifi cation in this section should lead.
Setting suspicion and patient referral 
to hematologist
Th e most common fi nding leading to suspicion of 
B-CLL is absolute lymphocytosis in routine blood ex-
amination (70%-80%), and less frequently (20%-30%) 
the fi nding of organomegaly (swollen lymph nodes 
and/or spleen) or symptoms associated with CLL.
Diagnosis and diff erential diagnosis
It is mandatory to make the diagnosis of typical 
B-CLL on the basis of morphology and fl ow cytom-
etry in peripheral blood sample and to distinguish it 
from other entities in the CLL syndrome. For the di-
agnosis of B-CLL phenotype (typical phenotype), the 
following is required: restriction of sIg light-chain ex-
pression of low intensity, CD5+, CD19+, CD20low, 
CD23+25. Basic hematologic clinical fi ndings and 
blood count allow for quantifi cation of the tumor mass 
in peripheral blood and lymphoid organs, which en-
ables classifi cation of entities that meet the diagnostic 
criteria for:
(1)  B-CLL (presence in the blood of more than 
5x109/L clonal cells), or
(2)  SLL (less than 5x109/L clonal cells in the 
blood and clonal lymphadenopathy greater 
than 1.5 cm), and
(3)  MBL (less than 5x109/L clonal cells in the 
blood and no clonal lymphadenopathy or 
symptoms).
So, a diff erent size of the tumor mass between 
B-CLL and MBL is critical and tumor distribution is 
critical for distinction between B-CLL and SLL.
It is evident that for the diagnosis of disease type, a 
very small number of tests could be considered suffi  -
cient because if the result is positive in peripheral 
blood (PB), it is not necessary to analyze bone marrow 
(BM) or lymph nodes (LN), although these tests have 
their place in further diagnostic work-up. For the diag-
nosis of SLL, it is recommended to make lymph node 
biopsy to establish the diagnosis, and radiological as-
sessment (ultrasound (US) or computed tomography 
(CT)) of the neck, thorax, abdomen and pelvis can be 
useful to distinguish between MBL and SLL.
Other B-cell malignancies that can be accompa-
nied by increased lymphoid cell counts in the blood 
should be taken in consideration in diff erential diag-
nosis. Distinction to CLL is usually made by fl ow cy-
tometry assessed immune phenotype. Th e majority are 
B-cell malignancies such as follicular lymphoma (FL), 
mantle cell lymphoma (MCL), marginal zone lym-
phoma (MZL), prolymphocytic leukemia (PLL) and 
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hairy cell leukemia (HCL), which all together repre-
sent less than 15% of all lymphoid appearing leukocy-
toses, and less than 5% express T-cell lineage marker 
variants.
It should be remembered that this type of disorder 
classifi cation based only on the immune phenotype is 
not using morphological, cytogenetic, molecular, or 
other characteristics of the diseases that today show 
signifi cant association with prognosis.
Evaluation of the stage/extent of the disease
After the diagnosis, the next step is evaluation of 
the disease stage or extent. It is based on clinical and 
Table 2. Clinical stages and TTM
Rai stages 
STAGE DESCRIPTION RISK
0 Lymphocytosis, in peripheral blood >15x109/L and >40% in bone marrow Low
I Stage 0 with enlarged lymph node (nodes) Intermediate
II Stage 0-I with splenomegaly, hepatomegaly or both Intermediate
III* Stage 0-II with hemoglobin <110 g/L High
IV* Stage 0-III with platelets <100x109/L High
* immune cytopenias do not fi t in this stage defi nition
Binet stages
STAGE DESCRIPTION RISK 
A Hemoglobin ≥100 g/L and platelets ≥100x109/L and <3 involved regions** Low
B Hemoglobin ≥100g/L and platelets ≥100x109/L and ≥3 involved regions Intermediate
C* Hemoglobin <100g/L and/or platelets <100x10
9/L and any number of 
involved regions High
** immune cytopenias do not fi t in this stage defi nition
**  the fi ve lymphoid areas comprise uni- or bilateral cervical, axillary and inguinal lymphoid, hepatomegaly and 
splenomegaly
TTM-score
COMPARTMENT REPRESENTATIVE SIZE RISK 
TM1 - BM and PB Lymphocyte count (peripheral blood) 9 Low
TM2 - Ly nodes Diameter of largest palpable node cm 9-15 Intermed
TM3 - spleen Palpable spleen (below left costal margin) cm >15 High
TTM TM1+TM2+TM3
Continuous 
variable
|ly| = absolute number of lymphocytes; TTM = Total Tumor Mass score
Note: if the largest lymph node is found by imaging (US or CT), those values should be used for TM2
Tumor Mass Distribution (TD) is calculated as quantitative parameter according to formula:
TD = TM1TTM .
Doubling Time of TTM (DT) is calculated as quantitative parameter according to formula:
DT = M × TTMbegTTMend – TTMbeg,
where TTMbeg is the size of TTM at the beginning of period M: TTMend is TTM size at
the end of period M; M is interval between TTMbeg and TTMend in months.
M should be at least 3 months.
Electronic calculator available online at: http://www.krohem.hr 
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hematologic evaluation, under the criteria shown in 
Table 2. Clinical stages represent a simple tool for 
clinical assessment of the disease extent. Th e basis of 
these systems is the assumption that the disease is 
gradually progressing and expanding. Th erefore, the 
patients who have advanced disease have a higher tu-
mor load and more extensive disease26-28.
Th e clinical stages according to Rai and Binet as-
sess tumor size by simple parameters, which estimate 
the size of the tumor mass (without precise quantifi ca-
tion of the aff ected compartments), along with the pa-
rameters for the assessment of bone marrow failure. In 
doing so, the greatest prognostic power contribution 
has the failure of bone marrow. Note that it is not a 
direct but an indirect sign of tumor size. Th eir prog-
nostic power is relatively weak if the failure of the bone 
marrow is excluded.
Th e estimation of the size of the Total Tumor Mass 
(TTM) is diff erent in that it quantitatively evaluates 
tumor mass in 3 major cell compartments, regardless 
of bone marrow failure (Table 2). Quantitative charac-
ter enables unbiased monitoring of disease progression 
and is a very convenient tool for the assessment of 
therapeutic response (see later). In addition, in most 
patients who have both peripheral blood and lym-
phoid organs aff ected, it is possible to determine the 
type of distribution of the tumor mass by comparing 
leukemic (TM1) and lymphoid organ (TM2 +TM3) 
compartments29. Th is feature of TTM system enables 
to estimate the dynamics of disease progression and 
response to therapy and redistribution (see later)30.
Prognostic factors at diagnosis 
and predictors of response
Analyses of prognostic factors performed in the era 
when therapy had little eff ect on clinical course identi-
fi ed a number of clinical or laboratory factors31, de-
scribing broadly the natural course of the disease. 
Prognostic factors that can be determined immedi-
ately at diagnosis are primarily related to the addition-
al characterization of the tumor itself. Some of them 
do not change during evolution of the disease, such as 
the mutational status of IgVH genes that generally 
discriminate between more benign and more malig-
nant disease32-34, and it is currently suggested to be-
come minimal standard initial evaluation31. Until now, 
these were rarely used in routine clinical practice and 
other tests showing high correlation with mutational 
status are used instead, such as CD38 and ZAP-70 by 
fl ow cytometry and immunohistochemistry, with the 
higher value found to correlate with poorer progno-
sis35-44. Th e usefulness of these surrogate factors is still 
controversial. In contrast, cytogenetic and molecular 
tests (FISH) to determine del (11q22-23), +12; del 
(13q14), del (17p13)45 showed a strong independent 
prognostic eff ect and usually change (progress) over 
time. Also, fi nding certain mutations (including TP53, 
SF3B1, NOTCH1, etc.)46,47 can complement these 
fi ndings. Th ese tests are good predictors of response in 
the chemo-immunotherapy era and have proven to be 
useful to stratify patients into groups that react diff er-
ently to certain drugs4,48. Since they may change dur-
ing the course of disease, testing must be performed 
just before each new line of therapy. All these tests that 
further characterize neoplastic clone cells are techni-
cally demanding and expensive, but relatively inexpen-
sive compared to drugs, and for those validated the 
cost and eff ort are justifi ed. Predictive factors seem to 
change or even lose their predictive power with novel 
treatments. Likewise, failure to new treatments will re-
quire discovery of new predictors.
On the other hand, a number of additional factors 
more related to patient’s state also have a strong prog-
nostic power, so a number of diff erent parameters is 
often used, and multivariate analyses are performed to 
study their impact on prognosis49.
Because of the above, we distinguish three types of 
factors, given the causal relationship with B-CLL. 
First, those that are associated with B-CLL clonal 
neoplastic diseases (size distribution, growth rate of 
tumors, mutational status, CD38, ZAP-70, FISH) 
may be used as predictors of response to therapy, 
etc.28,32,33,45,50-52. Also, numerous other characteristics 
such as blood chemistry (serum beta2 microglobulin, 
sCD23 and serum thymidine kinase53-55), clonogenic56, 
kinetic, and computer assisted cell imaging have been 
shown to be related to prognosis57,58; second, those that 
are associated with organ failure (mixed groups, they 
may be due to both very underlying neoplastic diseases 
and to consequences of associated diseases, such as 
anemia, thrombocytopenia, the etiology of which 
should be carefully evaluated); and third, those factors 
that are associated with the patient but not directly 
with the neoplasm (age, gender, performance status, 
comorbidity), that correlate with fi tness and the ability 
to tolerate aggressive treatments40,59-62.
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On the basis of strong independent predictors, 
composite prognostic indices are calculated63-65, most 
recently the CLL International Prognostic Index 
(IPI)66. Th ey show very good prognostic power with 
respect to the length of survival in the chemo-immu-
notherapy (CIT) era, but much less so with new treat-
ments. Also, one should be careful using them to strat-
ify patients for treatment that is adapted to risk be-
cause a composite index usually consists of the factors 
that belong to each of the three above mentioned 
groups.
With new, more eff ective therapies, the prognostic 
landscape changes. Most of the important predictors 
in the CIT era lose their power, and new ones are yet 
to be identifi ed4,48.
Indications for treatment/the criteria 
for therapy initiation
Th e criteria for active disease that warrant initia-
tion of treatment are based on iwCLL criteria, and are 
amended with TTM (Table 3). Th e decision should be 
based solely on the assessment of parameters that are 
associated with neoplastic B-CLL clone6. For param-
eters that may be unrelated to the neoplasm, it is nec-
essary to carefully evaluate the extent to which the 
parameters are associated with neoplastic clone (e.g., 
fever, anemia, etc.). Criterion parameters can be classi-
fi ed into three distinct types:
1. Quantitative parameters for which threshold 
consensus is defi ned, which is considered to justify 
treatment initiation, such as anemia, defi ned by a cer-
tain level of hemoglobin, thrombocytopenia defi ned 
by platelet count, organomegaly defi ned by the size of 
spleen or lymph nodes.
2. Monitoring data to enable assessment of trends, 
for example, progressive cytopenia, progressive lymph-
adenopathy and/or splenomegaly, increased leukocyte 
count or TTM values (see the previous section). It 
should be emphasized that only measurement of dy-
namic parameters can directly evaluate progression of 
the disease, as opposed to the a priori estimate of a 
possible evolution described in the previous section 
(see Prognostic features at diagnosis section). Here, 
however, we should point out certain diffi  culties and 
ambiguities in quantitative measurement of the dy-
namic parameters, especially in the early stages of the 
disease. Th is imprecision in a priori defi nition of the 
criteria for progressiveness, despite a very attractive 
concept, often leads to decision delay until the mo-
ment when it reaches the absolute value of the thresh-
old that is set up as described above.
3. Qualitative criteria of the occurrence of symp-
toms threatening organ damage and the like, consid-
ered to be the result of neoplastic disease activity.
Today, we seek to combine threshold criteria with 
dynamic criteria (see Table 7). Note that a number of 
criteria, the criteria of threshold, dynamics and quali-
tative changes may be used. Although it is suffi  cient to 
indicate treatment by the presence of only one of the 
stipulated criteria, it is important that this criterion is 
compelling, and the presence of multiple criteria makes 
decision certainly easier. It especially holds for dynam-
ic criteria, so it is good to compare the growth trend of 
the tumor mass with the trends of deepening anemia 
and/or thrombocytopenia. Th e indication for treat-
ment (according to KROHEM guidance) should be 
documented in patient records.
Th e schedule of activities and assessments
Table 4 shows the general scheme of tests that are 
used in pretreatment work-up, in therapy monitoring, 
and after therapy. Of the newly diagnosed CLL pa-
tients, about 10% require therapy immediately, so the 
pretreatment work-up is done immediately at diagno-
sis and visits 1-3 are completed without delay. Other 
patients (90% of all diagnosed) are observed after di-
agnosis at periodic visits until meeting the criteria for 
initiation of treatment. At that point, complete pre-
treatment work-up is performed. About 30% of all di-
agnosed patients never reach the criteria for initiation 
of treatment, while about 60% of all diagnosed patients 
reach the criteria, but in diff erent periods, from several 
months to more than 10 years.
It is possible to distinguish several specifi c clinical 
questions that need to be answered in stipulated visits 
and require diff erent extent of investigations. Th ese 
questions are answered in the following visits: (1) di-
agnosis, diff erential diagnosis, evaluation of the extent 
of disease, and preferably but not mandatory, assess-
ment of prognostic groups that require investigations 
(a-f ). At this time, it is recommended to evaluate gen-
eral health profi le (j); (2) repetitive visits monitoring 
clinical and hematologic parameters that serve as cri-
teria for initiation of treatment, based on simple pa-
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Table 3. Criteria for active (progressive/symptomatic) disease
CRITERION THRESHOLD DYNAMICS QUALITATIVE COMMENT
1 Hemoglobin <100 g/L Trend (worsening)
Th e level of anemia that is 
used in determining clinical 
stages according to Rai and 
Binet.
2 Platelets <100x109/L Trend(worsening)
Th e level of thrombocytopenia 
that is used in determining 
clinical stages according to Rai 
and Binet.
3 High tumor mass TTM >15 TTM DT <12 mo
Below 9 is not a suffi  cient 
criterion, between 9 and 15 is a 
‘gray zone’, above 15 is an 
indication present.
Lymphocyte count in itself is 
not a suffi  cient criterion, 
except for extreme cases 
(TTM >15 = lymphocytes 
>225x109/L)
4 Massive splenomegaly 
>6 cm below LCM
or
US >20 cm 
(progressive) Pain
Usually they are combined, but 
not necessarily. Dynamic 
parameters involved in TTM 
5 Massive lymph nodes >10 cm (progressive) Pain
Usually they are combined, but 
not necessarily. Dynamic 
parameters involved in TTM
6 Th reat to organ 
function
Clinical judgment For example, compressive 
symptoms
7
B symptoms 
defi ned as any one 
or more of the 
disease-related 
symptoms or 
signs:
Unintentional weight 
loss >10%/6 months; 
or
Signifi cant fatigue 
(ECOG PS 2 or 
worse); or
Fever >38 oC for 2 or 
more weeks without 
evidence of infection; 
or
Night sweats for more 
than 1 month without 
evidence of infection 
Usually they are combined, but 
not necessarily. Th e proposed 
system has long been used, 
particularly in lymphomas, and 
is well validated. Th e presence 
of B-symptoms is an 
important and indisputable 
element of therapeutic 
indications. It suffi  ces that one 
is present, but there may be 
several present simultaneously.
8
Autoimmune 
anemia or 
thrombocytopenia
Poorly responsive 
to standard 
therapy
Standard therapy does not 
imply anticancer drugs, but 
includes corticoids
Hypogammaglobulinemia, monoclonal or oligoclonal paraproteinemia, or absolute lymphocyte count do not by themselves constitute an 
indication for therapy. It is out of 8 groups of criteria theoretically possible to identify 11 individual indications based on exceeding a 
threshold, 3 dynamic evaluation of continuous quantitative parameters, where individual trends can be compared and thereby gain addi-
tional derived criteria, and 4 qualitative assessments. Although in principle the presence of at least one indication is suffi  cient, we should 
avoid making decisions on an isolated indication. It is clear that a larger number of indications further reinforces the decision to begin 
treatment. It is possible to decide that the patient needs to document the presence of at least two or more of the above indications for active 
(progressive/symptomatic) disease. Th e indication for treatment (according to KROHEM guidance) should be documented in patient 
 records!
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rameters (investigations a, b, c, j). Th e time between the 
visits may vary from weeks to months; (3) immediate 
pre-therapeutic work-up provides defi nite classifi ca-
tion of the disease, defi nitive assessment of prognostic 
parameters, as well as the general state of the patient, 
and any associated illnesses including infection status. 
For this reason, this visit should be most complete, en-
abling stratifi cation and providing baseline parameters 
for treatment; (4) these repetitive visits to monitor the 
course of therapy should be tailored according to the 
needs of respective therapy; and (5) end of therapy 
(EOT) visit should enable evaluation of the response 
achieved. After that, for CIT that is time limited, 
monitoring visits without therapy (2’) are repeated 
again and in case of the need for a new line of therapy, 
repeat visits 3’, 4’ and 5’ are scheduled. Th e situation is 
diff erent for novel agents since this treatment is at 
present unlimited and visits 4 should enable detection 
of treatment failure.
Th erapy individualization – defi ning goals 
and strategies, and stratifying patients
At the end of diagnostic procedure described above, 
there is a need to make decision on therapy, which will 
refl ect individualization of the respective patient. De-
cision is based on the integration of the factors related 
to the neoplasm on the one hand and the factors re-
lated to the patient on the other hand. According to 
new circumstances and new emerging paradigm be-
cause of the lack of curative treatment, initial therapy 
should maximize effi  cacy while minimizing overall 
toxicity. Th e overall approach is essentially based on 
clinical judgment and the expertise.
In general, we are comparing two risks: the risk of 
disease and the risk of treatment. It is clear that the 
risk of treatment should be reasonably lower than the 
risk of disease.
Th e risk of disease. Some treatments have been 
shown to be ineffi  cient in some disease subsets. How-
ever, novel treatments are also active in those subsets, 
which will diminish the importance of stratifi cation 
according to FISH and TP53, which was necessary 
until now. Nevertheless, since CIT has proved very ef-
fective in some subsets of patients and contraindicated 
in others, the classifi cation according to risk should 
remain until head-to-head comparisons resolve pend-
ing questions.
Th e risk of therapy, i.e. tolerance (or acute treatment 
toxicity) is highly dependent on the general condition of 
the patient and the presence of associated diseases, 
which is often associated (though not exclusively) with 
the patient’s age. However, treatments with new B-cell 
receptor inhibitors (BRI) have much better toxicity pro-
Table 4. General schedule of investigations before, during and after therapy
Visits→ 1 2* 3 4** 5 (2’→3’) (4’,5’)
Investigations
↓ @ dg
Monitoring 
to meet criteria 
for treatment
Pre-th work-up Th  monitoring EOT evaluation
After therapy repeat 
2’-5’
before new line (3’)
a History/PE + + + + + +
b Hematology + + + + + +
c TTM/stage + + + + + +
d Flow cytometry + + + +
e FISH 
CLL(4)/
Molecular +
b + +
f Cyto/Histo +b + + +
i Imaging + + +
j Otherclin ind + + + + + +
k Research b + + + + + +
*Monitoring protocol frequency varies depending on clinical condition from several weeks to several months, or even one year if the situa-
tion is stable, without change. However, in the emergence of new circumstances, it is necessary to check-up early; **these repetitive visits 
depend on treatment applied. For novel agents with at present unlimited duration, these visits should enable detection of treatment failure; 
bpreferred but not required tests.
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fi le that diminishes the importance of stratifi cation ac-
cording to fi tness, which was necessary in the chemo-
immunotherapy based paradigm. Nevertheless, for the 
same reason as described above, this stratifi cation should 
remain for CIT. Since CIT is not indicated in patients 
with del(17p)/TP53 mutation, the distinction between 
fi t and unfi t becomes irrelevant.
A patient is classifi ed as capable (fi t, Go Go) when 
there is a low comorbidity score (e.g., CIRS-G <6). Al-
though age does not enter in the calculation of CIRS-
G, it is known that age is a very important factor and it 
should be taken into account. It is common to impose 
an age limit for stratifi cation in therapeutic groups. To-
day, the limit is set at 65 years. Patients aged over 65 can 
be considered capable for receiving aggressive therapy if 
in excellent health, without substantial comorbidity.
On the basis of the two above-mentioned principles, 
patients are today stratifi ed into three strata with respect 
to antineoplastic therapy: (1) without the p53 gene de-
letion with good general condition (capable for aggres-
sive, fl udarabin based CIT therapy) – (LOW RISK + 
FIT), (2) without the p53 gene deletions with poor gen-
eral condition (incapable for aggressive therapy) – 
(LOW RISK + UNFIT), and (3) deletion of (17p)/TP 
53 mutation (HIGH RISK + FIT/UNFIT). For those 
patients, no further division according to fi tness is nec-
essary, since the new approved treatments are well toler-
ated16,17,67,68. In other words, these strata may in principle 
represent the combination of risk (high correlation with 
TP53 abnormality) and age (high correlation with fi t-
ness). However, for the reasons stipulated above, the 
chronologic age cut-off  should not be rigid, so as to al-
low elderly patients in good health to enjoy the benefi t 
of more aggressive treatment, and vice versa, to spare 
younger patients with comorbidity of unwarranted 
therapy associated risks.
Th e stratifi cation is used for guidelines and refl ects 
general principles, but for each patient, treatment plan 
should be individualized and set up after careful clini-
cal evaluation, also taking into account patients’ prefer-
ences.
Th erapeutic procedure
Th erapeutic recommendations based 
on evidence/clinical trials
Th e treatment for B-CLL consists of antineoplas-
tic therapy and supportive measures. Antineoplastic 
measures consist traditionally of chemotherapy, thera-
peutic antibodies, radiotherapy, stem cell transplanta-
tion methods, and recently novel agents that include 
B-cell receptor signal transduction inhibitors (BRI) 
and bcl-2 antagonists. In these guidelines, the recom-
mendations are based on phase 3 clinical trials, in some 
cases on evidence from earlier phase trials, and on the 
approved agents and therapies in Croatia. Combina-
tion therapy is generally more effi  cient than mono-
therapy.
Choice of antineoplastic treatment options 
– new therapeutic paradigm
Because this disease is generally not curable, occurs 
in elderly population, and often progresses slowly, it is 
most often treated in a conservative fashion. In asymp-
tomatic patients, treatment may be deferred until the 
patient becomes symptomatic as the disease progress-
es69. Th is concept is still valid and the treatment out-
side clinical trials is recommended only for patients 
that fulfi ll the indications described. Since the rate of 
progression may vary from patient to patient, with 
long periods of stability and sometimes spontaneous 
regressions, frequent and careful observation is re-
quired to monitor the clinical course5. At present, 
about 30% live without symptoms and never need 
therapy. Others will progress sooner or later, and will 
meet the criteria for therapy introduction.
Th e new, very eff ective treatments have recently 
dramatically changed the therapeutic landscape and 
led to change in the current CIT based paradigm into 
a new one. In comparison to therapies available to 
date, the new treatments show markedly improved ef-
fi cacy and considerably better tolerance. Th is has an 
impact on all aspects of patient management and 
choice of treatment options. Th is also goes for defer-
ring therapy, but at present there are no data to support 
early treatment. Current and future clinical trials that 
include novel agents in this setting may change this 
current concept. For patients in whom the criteria for 
therapy initiation are met, the general principle in the 
new paradigm is that (because no curative therapy has 
yet been found) initial therapy should maximize effi  -
cacy with improvement of overall survival (OS), while 
introducing the least overall toxicity, both short term 
and long term. Standard chemotherapeutic agents in-
duce not only cytopenias and sometimes fatal infec-
tions (acute treatment toxicity) but also mutational 
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Fig. 1. Flow chart describing B-CLL diagnosis and treatment 2017 paradigm shift.
Th is chart shows diagnostics based decision steps (orange rectangles) and their sequence (orange arrows), currently approved therapies by 
EMA (in 2/2017) (blue rectangles), as well as the sequence for fi rst-line treatment (green arrows) and salvage treatment lines (blue arrows). 
Th e minority of patients (about 10%) present with indication for treatment at diagnosis, while the majority are observed until the criteria 
for treatment are met. Th is part (framed) did not change. When the indication is present, B-CLL patients are eligible for fi rst-line treat-
ment. In this part, major changes have occurred because of recent approval of new options. Ibrutinib monotherapy is approved as continu-
ous treatment of undetermined duration or until progression or unmanageable toxicity for all patient strata because of favorable effi  cacy/
tolerance ratio in disease control. Th is is a new approved option, so that ibrutinib could be used to start the new path. In case of progression 
or toxicity, patients qualify for second-line treatment (approved option is venetoclax). If this fails, the patient is eligible for experimental 
treatments (combinations of novel agents with immunotherapy, allogeneic stem cell transplantation, CAR-T cell therapy, and the like). 
Th eoretically, all of these could be done without further diagnostics and stratifi cation, while avoiding chemotherapy. However, head-to-
head comparison data between novel agents and chemo-immunotherapy (CIT) are still lacking. CIT, although associated with higher 
short- and long-term toxicities, has proved to be highly eff ective in achieving long, durable remissions and perhaps even a cure in some 
patient subsets. It was therefore in the CIT era essential to identify those who would respond, and a number of predicting factors have 
emerged in this setting. Th e NGS has revealed that intratumoral heterogeneity and genomic changes can be used for better CIT response 
prediction. Most important for CIT clinical use are two predictors, del(17p)/TP53mut and IGHV mutation status. Th e former can iden-
tify patient subset in which chemotherapy is ineff ective and even contraindicated because of inducing adverse clonal evolution, and the 
latter can identify disease type, where patients with unmutated IGHV poorly respond to CIT and even if they respond, the response is short 
and clones that are more resistant emerge. Both predictors are considered standard minimum for stratifi cation. If adverse features are pres-
ent, the patients should be treated with ibrutinib or idelalisib in fi rst line. Others may continue towards CIT that is tailored according to 
age and comorbidities. Fit patients qualify for FCR, unfi t for Clb+Obi or like, and patients ‘in-between’ for BR. If they relapse late, the CIT 
may be repeated, tailored to current fi tness, while early relapsed/refractory patients qualify for BRI or venetoclax salvage. At present, base-
line stratifi cation based on genetically defi ned risk, as well as on age and comorbidities to tailor treatment intensity is still needed for CIT, 
although fi tness is currently not important for novel agents. Th e current CIT based paradigm (shown horizontally) is losing importance and 
the new paradigm (shown vertically) is likely to take over. However, it will require identifi cation of new important predictors along the new 
path, since the majority of predictors identifi ed for CIT lose their power in the new setting. As data accumulate, new predictors will emerge 
for this setting. High throughput NGS has begun to identify new predictors for targeted therapy response, as well as new predictors of 
failure at molecular level, as treatment proceeds. All this may eventually lead to a new upfront stratifi cation for risk adapted precision 
medicine therapy in B-CLL. Th e ongoing trials and head-to-head comparison of novel agents and their combinations with immunother-
apy versus CIT are under way. Th ey will hopefully resolve current dilemmas. Novel therapy research including genomic diagnostics is likely 
to off er new options that will eventually lead to time limited therapies, without chemotherapy.
Dg = diagnosis; WW(I) = watch and wait (investigate); Ind = indications for treatment; PF = predictive factors; Late R = late relapse; 
Early R/R = early relapsing or refractory; IBR = ibrutinib; IDELA = idelalisib; VEN = venetoclax; Exp = experimental treatment; CIT = 
chemo-immunotherapy
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damage to the genome that can manifest as more ag-
gressive and refractory phenotypes upon relapse and 
can induce second malignancies. For this reason, 
avoiding chemotherapeutic agents upfront, when pos-
sible, is a new paradigm of sequencing therapy for 
CLL5. Major changes are explained in Figure 1.
However, in the absence of head-to-head random-
ized trials to assess effi  cacy/tolerance ratio between 
novel therapies and best CIT for fi t patients, in this 
subset CIT should not be abandoned. Also, the access 
and availability of new treatments will need some time, 
and the current cost of novel treatment may be out of 
reach for insurers.
Treatment options and current labels 
for approved antineoplastic medications
Observation. For patients who do not fulfi ll the 
criteria for starting therapy, the treatment is observa-
tion. Although it is in contrast to general oncologic 
tendency to treat patients with neoplasms as soon as 
possible, no data exist to suggest any harm in deferring 
therapy in those patients. Since the rate of progression 
may vary, frequent and careful observation is required 
to monitor the clinical course.
Ibrutinib. Ibrutinib is a selective irreversible in-
hibitor of Bruton tyrosine kinase, a signaling molecule 
located upstream in the B-cell receptor-signaling cas-
cade. Label: IMBRUVICA as a single agent is indi-
cated for the treatment of adult patients with previ-
ously untreated CLL; IMBRUVICA as a single agent 
or in combination with bendamustine and rituximab 
(BR) is indicated for the treatment of adult patients 
with CLL who have received at least one prior the-
rapy70. Th ose indications have been approved based 
on the randomized phase 3 studies RESONATE-2 
(PCYC-1115-CA), RESONATE and HELIOS71-73.
Idelalisib. Idelalisib is an oral inhibitor of the delta 
isoform of phosphatidylinositol 3-kinase, which is lo-
cated in the B-cell receptor-signaling cascade. Label: 
ZYDELIG is indicated in combination with an anti-
CD20 monoclonal antibody (rituximab or ofatumum-
ab) for the treatment of adult patients with CLL who 
have received at least one prior therapy, or as fi rst-line 
treatment in the presence of 17p deletion or TP53 mu-
tation in patients who are not eligible for any other 
therapies74. Approval is based on randomized, double-
blind, phase 3 study75 and phase 2 study76.
Rituximab. Rituximab is a murine anti-CD20 
monoclonal antibody. Label: MABTHERA is indi-
cated in combination with chemotherapy for the treat-
ment of patients with previously untreated and re-
lapsed/refractory CLL77. Approval was based on ran-
domized phase 3 studies with fl udarabine and cyclo-
phosphamide (FCR)78,79, bendamustine (BR)80,81, and 
chlorambucil82,83.
Obinutuzumab. Obinutuzumab is a human anti-
CD20 monoclonal antibody. Label: GAZYVARO in 
combination with chlorambucil is indicated for the 
treatment of adult patients with previously untreated 
CLL and with comorbidities making them unsuitable 
for full-dose fl udarabine based therapy84. Approval is 
based on a randomized phase 3 study82.
Ofatumumab. Ofatumumab is a human anti-CD20 
monoclonal antibody. Label: ARZERRA is used in 
previously untreated patients who cannot be treated 
with fl udarabine; in these patients, it is used together 
with chlorambucil or bendamustine (other cancer 
medicines); in patients whose disease has not respond-
ed to previous treatment (known as refractory disease) 
with fl udarabine and a medicine called alemtuzumab; 
and in patients whose disease has come back after pre-
vious treatment (known as relapsed disease). In these 
patients, ARZERRA is used together with fl udarabine 
and cyclophosphamide85. Approval is based on a ran-
domized phase 3 study in combination with chloram-
bucil COMPLEMENT-186.
Alemtuzumab. Alemtuzumab, a monoclonal anti-
body directed at CD52. Th e drug was withdrawn for 
CLL indication by the producer because of commer-
cial reasons. However, the company can off er the drug 
on request for compassionate use free of charge. Label: 
(EMA EPAR 2011 authorization withdrawn). MAB-
CAMPATH is used to treat patients with B-cell CLL 
for whom treatment combinations including fl udara-
bine are not appropriate87. Approval was based on ran-
domized clinical trials and showed activity in TP53 
mutation88-90.
Venetoclax. Venetoclax is a highly selective inhibi-
tor of Bd2. Label: VENCLYXTO monotherapy is 
indicated for the treatment of CLL in the presence of 
17p deletion or TP53 mutation in adult patients who 
are unsuitable for or have failed a B-cell receptor path-
way inhibitor. Venclyxto monotherapy is indicated for 
the treatment of CLL in the absence of 17p deletion 
or TP53 mutation in adult patients who have failed 
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both chemo-immunotherapy and B-cell receptor 
pathway inhibitor91. Approval is based on a phase 1 
escalation study92 and phase 2 study93.
Oral alkylating agents with or without cortico-
steroids. Chlorambucil was used for the treatment of 
CLL for more than 60 years. Label: LEUKERAN is 
indicated for the treatment of CLL94. Although the 
role of chlorambucil has considerably diminished, reg-
ulators paradoxically still accept drugs for registration 
on the basis of phase 3 trials, which use chlorambucil 
in very low doses as comparator89,95,96, while claiming 
at the same time that the therapeutic success of such 
therapies is extremely modest. Th us, low doses are still 
considered standard therapy, although it was shown 
that medium and especially high doses had signifi -
cantly greater eff ectiveness97-100. A meta-analysis of six 
trials of immediate versus deferred therapy with chlo-
rambucil showed no diff erence in OS at 10 years69.
Purine analogs. Fludarabine is a purine analog, 
one of a group of chemotherapy drugs known as anti 
metabolites. Th ey stop cells making and repairing 
DNA. Cancer cells need to make and repair DNA in 
order to grow and multiply. Label: Fludarabine (gen) 
is used in the treatment of B-cell CLL in patients with 
suffi  cient healthy blood cell production. First treat-
ment for CLL with this medicine should only be start-
ed in patients with advanced disease having disease 
related symptoms or evidence of disease progression101. 
Approval is based on a phase 3 randomized study95. 
Th is drug is also used in combination therapies (see 
below).
Bendamustine. Bendamustine is a cytotoxic agent 
with bifunctional properties of an alkylator and a pu-
rine analog. Label: bendamustine (gen) is used as 
monotherapy or in combinations with other drugs for 
treatment of CLL in cases when combination chemo-
therapy containing fl udarabine is not appropriate102. 
Approval is based on a randomized phase 3 trial for 
monotherapy103 and for combinations on phase 2 trials 
in previously treated80 and untreated patients81.
Combination therapy
Fludarabine based combinations include FCR, 
FCOfa, FR, and FC. Fludarabine plus cyclophospha-
mide plus rituximab has proved very eff ective in those 
patients who can tolerate the treatment. For this rea-
son, in the last 10 years, FCR has become the gold 
standard of CIT for fi t patients78. Long-term results 
have confi rmed overall effi  cacy and a subset of long-
term responders defi ned by genomic risk groups has 
emerged104-106. Although no head-to-head compari-
sons have yet been completed in line with the new 
paradigm, the indication is narrowed to a subset of fi t 
patients with hypermutated IVGH in whom the like-
lihood of very long remission may outweigh the con-
cerns of chemotherapy toxicity.
Bendamustine combinations are used in those pa-
tients in whom fl udarabine cannot be tolerated. In 
head-to-head comparison to FCR, BR combination 
was found inferior107.
Combination therapy without anti-CD20 mono-
clonal antibodies. For FC, CVP and CHOP, a meta-
analysis of ten trials compared combination chemo-
therapy (before the availability of rituximab) with 
chlorambucil alone and showed no diff erence in OS at 
5 years69.
Combination with novel agents. It is likely that 
combinations of BRI and Bcl2 inhibitors with anti-
CD20 antibodies will be the basis in the era of the new 
emerging paradigm. At present, only ibrutinib + 
bendamustine + rituximab and idelalisib + anti-CD20 
monoclonal antibodies are approved.
Bone marrow and peripheral stem cell transplan-
tations. Although this modality is considered the only 
option for cure, it is still under clinical evaluation, es-
pecially in the context of novel agents and new emerg-
ing paradigm108,109.
Th e overall therapeutic eff ect is a consequence of 
total therapeutic interventions, including antineoplas-
tic and supportive measures that are particularly im-
portant.
Criteria for evaluation of response to therapy
Table 5 shows the criteria for assessment of thera-
peutic eff ect. Th e criteria generally used the same 
grounds, based on the estimation of the tumor mass 
parameters in diff erent compartments on the one 
hand, and the parameters for the assessment of myelo-
poiesis on the other hand. Th e criteria are somewhat 
diff erent in the current NCI/iwCLL criteria6,13 and 
the criteria described below (IGCI, EORTC)97-99,110,111.
To monitor the dynamics of the disease (both pro-
gression and response to therapy), TTM score (de-
scribed in clinical stage) is very convenient because it 
is the only clinical system that is based on a continu-
ous, quantitative parameter that is easy to apply and 
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NCI based criteria, but TTM shows the advantage 
in assessing partial remission (PR) by comparing 
total tumor mass before and after treatment, so it is 
possible to set a minimum threshold for minimal re-
mission (MR), e.g., reduction by >25%, partial remis-
sion (PR) >50%, and very good PR >75% and more. 
Likewise, the TTM based criteria are more accurate 
and without bias on estimating stable disease (SD) and 
progressive disease (PD). Th e continuous quantitative 
character of TTM size allows for comparison of trends 
between the criterion group A (TTM) and group B 
(function of residual normal hematopoiesis). It is 
 possible to evaluate the benefi cial antineoplastic eff ect 
of therapy independently of the toxic eff ect on hema-
topoiesis.
validated in thousands of patients in various interna-
tional clinical trials. To estimate the doubling time 
(DT), it is more reliable than just the number of lym-
phocytes because it can compensate for changes in the 
distribution of the tumor mass occurrence after the 
administration of corticosteroids or TKIs, when there 
may be an increase in the number of leukocytes while 
reducing the nodes or spleen. For this reason, the NCI/
iwCLL criteria have recently been amended, but are 
still suboptimal for monitoring disease response23,112, 
while the TTM scoring system is much better for 
measuring redistribution of clonal cells among com-
partments30,113.
When assessing the response to therapy, complete 
remission (CR) is assessed equally in the TTM and 
Table 5. Defi nition of response to treatment (NCI updated guidelines, Blood 2008)
PARAMETER CR1 PR1 PD1
NCI / 
IWCLL
Group A
Lymphadenopathy2 Th ere is none >1.5 cm Decrease ≥50% Increase ≥50%
Hepatomegaly No Decrease ≥50% Increase ≥50%
Splenomegaly No Decrease ≥50% Increase ≥50%
Lymphocytosis 
in blood
<4x109/L Decrease ≥50% 
from baseline
Increase ≥50% from 
baseline
Bone marrow3 Normocellular, <30% 
lymphocytes, No 
B-lymphoid nodules.
Hypocellular marrow 
defi nes CRi. 
50% reduction 
of marrow infi ltration 
or B lymphoid nodules.
Group B
Platelets >100x109/L >100x109/L or increase 
≥50% from baseline
Reduction by ≥50% from 
baseline as a result of CLL
Hemoglobin >110 g/L >110 g/L or increase 
≥50% from baseline
Reduction by >2 g/dL from 
baseline as a result of CLL
Neutrophils3 >1.5x109/L >1.5x109/L or >50% 
improvement from 
baseline
TTM*
(EORTC/
IGCI/
KROHEM) 
TTM TTM <2 (lymphocytosis 
<4x109/L, no 
lymphadenopathy, 
no organomegaly)
TTM decrease ≥50% 
and TTM<9
TTM increase ≥25%
BM function (Plt, Hb, Neutro): same as NCI/IWCLL (group B)
Group A criteria defi ne tumor mass, group B criteria defi ne hematopoietic system (or bone marrow) function.
1 CR (complete remission): all criteria must be present, and patients must be without general symptoms associated with CLL; PR (partial 
remission): at least two criteria in group A plus one in group B must be present; SD (stable disease) is the absence of progressive disease 
(PD) if at least PR is not reached; PD (progressive disease): at least one criterion from group A or B must be present.
2 Th e sum of the products of multiple lymph nodes (as evaluated by CT in clinical trials or by physical examination in general practice).
3 Th ese parameters are irrelevant for certain types of responses.
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Minimal residual disease (MRD) is an important 
end point, and should refl ect no measurable disease in 
the body. However, MRD testing should be standard-
ized and the sample source well defi ned. By doing this, 
we should avoid reports of MRD negative patients 
with persistent signifi cant organomegaly. Th ose cases 
in fact have ‘clean’ blood but sometimes may not fulfi ll 
common criteria for partial remission, and the term 
MRD without specifi cation is misleading.
Antineoplastic therapy 
– current treatment options
Th ere are several treatment options. Th erapeutic 
recommendations summary for fi rst-line treatment 
and for salvage treatment in major therapeutic strati-
fi cation groups are shown in respective tables.
Management of patients with no accepted 
criteria for therapy
If the patient is not showing any signs of active/
progressive/symptomatic disease, the antineoplastic 
therapy is not recommended, but the patient is moni-
tored and reviewed without therapy. Th us ‘Watch and 
Wait’ should be transformed to ‘Watch and Investi-
gate’ (W&I). Th is view is based on the evidence col-
lected in randomized trials during the 1980s, when it 
was shown that chlorambucil based treatment did not 
contribute to longer survival, moreover, despite the 
relative ease of controlling symptoms and achieving 
clinical remission, overall survival was marginally 
worse97,110,114. Until now, there are no data indicating 
that harm is due to deferring therapy in asymptomatic, 
stable disease. However, trials that are under way, 
which include novel agents and/or combinations, may 
change this concept, but it will take time since those 
trials require prolonged follow up.
While for these patients antineoplastic medication 
is not recommended, standard care should include in-
fection prophylaxis such as annual fl u and pneumococ-
cal every 5 years, and in case of infection early treat-
ment.
Initial treatment (fi rst-line treatment)
Th e fi rst-line treatment relates to previously un-
treated patients. All patients in standard care must 
have clinical indication for treatment initiation (i.e. 
must fulfi ll the criteria stipulated above). Recommen-
dation depends on the risk associated with B-CLL 
(High or Low) and patient general condition (Fit or 
Unfi t) (Table 6, Fig. 1). Each stratum will be discussed 
separately.
Initial treatment for patients with no del(17p/TP53 
mutation that are fi t (LOW RISK + FIT)
As a rule, the patients in this stratum (about one-
third of fi rst-line treatment) are younger than 65. 
Th erapeutic goal is to be set high, to achieve complete, 
durable remission, prolong survival, and perhaps even 
off er a possible cure.
FCR (fl udarabine, cyclophosphamide, rituximab) 
is recommended as a standard initial therapy for previ-
ously untreated fi t patients outside clinical trials78. Ac-
cording to the DCLLSG CLL8 protocol, 6 cycles at 
intervals of 28 days if the patients tolerate the treat-
ment well, and after EOT, no further treatment is an-
ticipated, only follow up visits. Long-term follow up 
identifi ed a subset of patients in whom long and du-
rable response was achieved105,106,115. Th ose patients had 
mutated IGHV, no 11q and were aged <65. Other pa-
tients may respond, but they tend to relapse soon. For 
this reason, for fi t patients aged <65, mutated IGHV 
and no 11q (nor del(17p)/TP mutation) who fulfi ll the 
criteria for treatment, FCR is the treatment of choice. 
In others, according to the new paradigm, it is sug-
gested to avoid chemotherapy, especially FC.
In patients who are unsuitable for fl udarabine ther-
apy, bendamustine + rituximab (BR) can be tried. It 
seems to be both less toxic and less eff ective.
Ibrutinib is also approved for this indication. Ac-
cording to the new paradigm, BRI may replace CIT 
but at present, there are no data of randomized trials to 
support it. Head-to-head comparison of FCR or BR 
with ibrutinib is under way and is likely to resolve this 
question.
Initial treatment for patients with no del(17p)/TP53 
abnormality that are unfi t (LOW RISK+UNFIT)
Th e majority of patients (more than 60% of treated 
in fi rst line) belong to this group. As a rule, the patients 
are older than 65, with comorbidity, and therefore not 
capable to tolerate aggressive CIT therapeutic ap-
proach; thus, it is necessary to modify therapeutic goal 
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this subset, since the TP53 mutated clone is not re-
sponding and CIT may enhance unfavorable clonal 
selection and is therefore harmful. We recommend for 
both fi t and unfi t the induction with ibrutinib or ide-
lalisib plus rituximab. Ibrutinib appears superior to 
idelalisib in all settings as fi rst choice BRI117-119. In se-
lected cases, this therapy can be followed by elective 
AlloSCT. HDMP plus rituximab120,121 or alemtuzum-
ab122 should be used if BCI therapy is unavailable.
Treatment for relapsed/refractory CLL
Th is relates to previously treated patients. Again, 
they should fulfi ll the criteria for retreatment, essen-
tially the same as described above. For this reason, time 
to progression (measured as PFS) is distinct from time 
to next treatment (TTNT). Th e situation in this set-
ting is much more complex, since in addition to four 
major therapeutic strata, special attention should be 
paid to previous treatment(s) (type of treatment, num-
and choose remission or stabilization of disease with a 
well-preserved quality of life.
We recommend chlorambucil plus one of the anti-
CD20 antibodies as a standard82,83,86,116. Best results 
have been published with chlorambucil + obinutu-
zumab.
Also, BR is an option of chemo-immunotherapy 
for patients with appropriate fi tness.
Ibrutinib is also approved for this indication be-
cause of excellent results in this patient subset. Ac-
cording to the new paradigm, BRI may replace CIT 
but at present, there are no direct data to support it. 
Head-to-head comparison of ibrutinib + obinutuzum-
ab with chlorambucil + obinotuzumab is under way 
and is likely to resolve this question.
Initial treatment for fi t/unfi t patients with del(17p)
/TP53 mutation (HIGH RISK + FIT/UNFIT)
In this stratum, we expect less than 7% of all pa-
tients treated in fi rst line. CIT is contraindicated in 
Table 6. First-line treatment of CLL (KROHEM v1 2017)
Stage % a Molecular cytogenetics %
 b General 
condition %
 b First-line treatment
Standard c
Asymptomatic;
Binet: A-B ; Rai 0-II; TTM<9 (15) 33 Irrelevant Irrelevant Nothing (W&I)
Binet C, Rai III-IV; TTM>15;
or symptomatic disease
(indication for treatment met)
67
No del(17p) /
TP53 mut 93
Fit 32
FCR (1)d
B + R e
Ibrutinib (1)
Unfi t 61
Chl + Obi (1)
Chl + R
Chl + Ofa
B + R
Ibrutinib (1)
del(17p)/
TP53 mut 7 Irrelevant 7
Ibrutinib
Idelalisib + R
HDMP+R
A f
Clinical trials are highly recommended for all subsets and we strongly believe that they improve the level of care.
a Projected percentages are based on compiled data from Western countries and Croatia.
b Percentages of patients with distinct general condition and molecular genetics groups refer to treated patients. Fit patients are less than 
65 years of age and with CIRS score less than 6. Younger patients with CIRS score of 6 and more and patients aged 65 years or more (re-
gardless of CIRS score) qualify as unfi t.
c Standard treatments are in order of preference, all are 2A or less according to NCCN consensus, treatments with higher grade are marked (1).
d In patients with hypermutated IGHV and no 11q.
e For less fi t patients.
f Alemtuzumab is withdrawn from market, but can be obtained free of charge from producer upon request.
FCR (fl udarabine, cyclophosphamide and rituximab); B = bendamustine; Chl = chlorambucil; R = rituximab; Obi = obinutuzumab; Ofa = 
ofatumumab; A = alemtuzumab; HDMP (high dose methylprednisolone).
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ber of treatment lines, the period that has elapsed from 
previous treatment, etc.). In principle, with the excep-
tion of very late relapses, the patients require more 
therapy to achieve less response.
Since the vast majority (>90%) of all CLL fi rst-line 
treated patients have no TP53 abnormality, their treat-
ment allocation was essentially dependent on their 
general condition (Fit or Unfi t). Th us, the fi t patients 
receive more aggressive treatment aiming at MRD 
negativity (hopefully eradication of the disease), while 
the unfi t patients receive less aggressive treatment that 
is less likely to achieve MRD negativity and conse-
quently the therapeutic aim is less ambitious.
Th e relapse is, therefore, primarily linked to the 
fi rst-line therapeutic stratum. It is an indicator of re-
spective therapy failure. In principle, the longer the 
period to relapse, the more eff ective fi rst-line treat-
ment was.
General principles of therapeutic strategies in re-
lapsing/refractory patients are shown in Table 7 and 
Figure 1. Th e relapsing patient in early relapse is con-
sidered refractory and requires change of therapy. If 
the treatment results in remission of long duration, it is 
reasonable to try the same treatment that has proved 
eff ective again in the relapse.
Table 7. Treatment of relapsed/refractory CLL (KROHEM v1 2017)
Relapse % a Molecular cytogenetics %
General 
condition %
Salvage treatment
Standard b,c Extended / Maintenance
Early (<2 years)
Refractory disease 
(<1 year)
30
No del(17p) /
TP53mut 22
Fit 7 Ibrutinib (1)
Idelalisib + R (1)
Venetoclax (1)c
HDMP + R
Ofa 
FCR d
B+R d
F + A e
→AlloSCT
→antiCD20 g
Unfi t 15
B + R
Chl + 
antiCD20 d 
→antiCD20 g
Del(17p) /
TP53mut 8
Fit &
Unfi t 8
Ibrutinib (1)
Idelalisib + R (1)
Venetoclax (1)f
HDMP + R
A e ± R
→AlloSCT (fi t)
→antiCD20 g
Late (>2 years) 70 70 Fit &Unfi t Repeat fi rst line (or choose from above)
Th e guidelines for salvage treatment are more complex than in fi rst-line treatment. It should take into consideration additional criteria 
depending on the type of treatment in fi rst line, and on the observed duration of response. Clinical trials are highly recommended for all 
subsets and we strongly believe that they improve the level of care.
a Projected percentages of early and late relapses are based on Dubrava University Hospital data for 2015 and 2016. Percentages of unfi t 
patients and patients with del(17p) tend to increase. Fit patients = less than 65 years of age and with CIRS score less than 6. Younger pa-
tients with CIRS score of 6 and more and patients aged 65 years or more qualify as unfi t;
b Standard treatments are in order of preference, but for each individual patient should be based on integration of clinical data and patient 
preference. All treatments are 2A according to NCCN consensus, treatments with higher grade or lower grade are marked;
c In patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor and chemo-immunotherapy;
d If not in 1st line;
e Alemtuzumab is withdrawn from market, but can be obtained free of charge from producer upon request;
fIn patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor;
g Ofatumumab is found to signifi cantly prolong PFS in responsive patients in second or third response to chemo-immunotherapy, approved 
by FDA.
FCR (fl udarabine, cyclophosphamide and R); B = bendamustine; Chl = chlorambucil; R = rituximab; Obi = obinutuzumab; Ofa = ofatu-
mumab; A = alemtuzumab; Allo SCT = allogeneic stem cell transplantation; HDMP (high dose methylprednisolone); antiCD20 (ofatu-
mumab or obinutuzumab or rituximab).
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For this reason, relapses will be described as a func-
tion of fi rst-line stratifi cation therapeutic failures. 
However, in all patients in relapse, TP53 status should 
be checked (before each new line of therapy) to assess 
whether the risk grade has changed in comparison to 
front-line stratifi cation. Most of the patients currently 
relapsing early were in fi rst line treated by CIT ad-
justed to fi tness status. Occasionally, some patients in 
fi rst relapse were in fi rst line treated by chemotherapy 
(chlorambucil, fl uradabine alone or in combination 
with cyclophosphamide).
Patients relapsing from the LOW RISK 
+ FIT stratum
Patients relapsing early are considered refractory 
and should be treated with ibrutinib, or idelalisib plus 
rituximab.
If the anti BCR drugs cannot be provided, the cur-
rent options include BR, HDMP+R, FA, other che-
mo-immunotherapy, ofatumumab and alloSCT.
Patients relapsing late who have not acquired TP53 
abnormality remain fi t enough for fl udarabine-based 
treatment, and those with a clinical indication for 
treatment may receive FCR, provided that they have 
mutated IGHV, no TP53 or 11q108,123. If the patient at 
the time of relapse changes to unfi t stratum, the re-
lapse treatment described in respective section applies.
Patients relapsing from the LOW RISK 
+ UNFIT stratum
Over 50% of all treated patients belong to this 
group. In this group, less aggressive treatment was ap-
plied in front line because these patients are not likely 
to tolerate FCR. Th e response obtained is less likely 
MRD negative and relapses are expected in a wide 
range from early (less than 24 months) or late (more 
than 24 months).
In case of early relapse, patient is considered refrac-
tory to given treatment and ibrutinib or idelalisib + 
rituximab is recommended. Less benefi t can be ex-
pected from BR or chlorambucil + antiCD20 or 
HDMP + R. In selected responsive cases, ofatumumab 
maintenance is applied.
In case of late relapse, the patients relapsing after 
chlorambucil can be retreated with chlorambucil + 
anti-CD20 monoclonal antibody116. Th is therapy may 
be repeated several times (in function of achieved du-
ration) until the duration of remission is shortened to 
2 years, after which it is justifi ed to go to the second-
line therapy (ibrutinib or idelalisib+R).
Patients relapsing from the HIGH RISK 
+ FIT/UNFIT stratum
Th ese patients are at a particularly high risk. If the 
patients did not receive BRI treatment, those drugs are 
recommended. If the patients relapse on BRI drugs, 
venetoclax or alternative BRI is indicated. If those are 
not available, HDMP + R or alemtuzumab ± R can be 
tried.
If the fi t patients were not previously allo trans-
planted, reinduction should be considered with diff er-
ent combinations (including ofatumumab) and if suc-
cessful, proceed to transplantation.
In selected responsive cases, ofatumumab mainte-
nance may be considered124.
Consolidation/Maintenance therapy
It has been observed that MRD negative remission 
is associated with prolonged progression free survival 
both in previously untreated125 and relapsed126 patients. 
Th is has led to studies of additional treatment in pa-
tients with residual disease post therapy. In line with 
the new paradigm, although chlorambucil mainte-
nance can prolong survival127, maintenance treatment 
should be chemotherapy free. Ofatumumab in selec-
tive responsive patients was shown to prolong PFS but 
not OS128, and is approved for this indication by FDA. 
Other anti-CD20 antibodies, although approved in 
some other B-cell malignancies129, are not yet approved 
in B-CLL by regulators. Lenalidomide was also shown 
to improve PFS, but is not yet approved by regula-
tors130,131.
As described earlier, BRI therapies are given for a 
prolonged period to maintain the response as distinct 
from chemo-immunotherapy. Early (months) period 
of treatment is characterized by marked tumor mass 
redistribution, so that monitoring should be adjusted 
accordingly (see section on response criteria).
Th e role of allogeneic transplantation
Th e indication for allogeneic SCT is currently 
changing in line with excellent results of BRI and 
venetoclax. Current indications include poor respond-
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ers to BRI and Bcl-2 antagonist, and appearance of 
Richter syndrome109.
Th e role of radiotherapy
Radiotherapy can provide eff ective palliation in 
cases with symptomatic bulky lymphadenopathy and 
should be off ered to patients in which chemo-immu-
notherapy has been ineff ective or is contraindicated. 
Low doses of external beam radiotherapy (2x2 Gy) can 
be highly eff ective in this situation and a higher dose 
(30 Gy in 2-3 Gy fractions) may be required in pa-
tients with transformed aggressive disease or those 
known to have a TP53 abnormality132.
Treatment of SLL
Th e biological similarities between SLL and CLL 
are so close that a similar response to treatment could 
be expected. Th is is supported by the MDACC single 
centre retrospective study133. Indications for and choic-
es of treatment are the same as for CLL. Rare patients 
in whom SLL is diagnosed following biopsy of an en-
larged lymph node in the absence of detectable disease 
at any other site may be off ered local radiotherapy with 
curative intent.
Risk of other diseases
Infections
Th e risk of infections is related to progressive de-
fect both in antibody- and cell-mediated immunity. In 
addition, therapy may worsen immune impairment, 
particularly fl udarabine and anti-CD20 antibodies, 
but also B-cell receptor inhibitors. For this reason, in-
fections represent a frequent cause of morbidity and 
mortality in CLL. Infections are typically bacterial and 
should be treated early. For those who have repeated 
infection and require repeated antibiotics, immuno-
globulin replacement therapy should be considered. 
Prophylactic vaccination is advised, but live vaccine 
should be avoided.
Autoimmune complications
Autoimmune complications are common in CLL, 
occurring in 10%-20% of patients134. Th ey almost ex-
clusively target blood cells, most commonly red blood 
cells. Hemolytic anemia (AIHA) is predominant and 
immune thrombocytopenia (ITP) is 4-5 times less 
common. A bone marrow aspirate is usually required 
to confi rm the diagnosis of autoimmune cytopenia.
AIHA or ITP should be treated before deciding 
whether therapy for CLL is needed. First-line therapy 
is prednisolone. Second-line therapies for patients in-
tolerant of or refractory to steroids include cyclospo-
rine, intravenous immunoglobulin (ITP), thrombo-
poietin mimetic agents (ITP), CVP, low-dose cyclo-
phosphamide, rituximab, alemtuzumab and splenec-
tomy135. CLL treatment may be initiated to control 
recurrent or refractory AIHA/ITP. Rituximab-con-
taining regimens are recommended in patients who do 
not have a TP53 abnormality. If AIHA/ITP develops 
during CLL treatment, the same regimen should be 
used again in this patient with extreme caution and 
only if no eff ective alternative is available. Autoim-
mune neutropenia usually responds to GCSF.
Prolymphocytic transformation
B-cell prolymphocytic transformation is diagnosed 
in progressive organomegaly and lymphocytosis with 
increase of prolymphocytes >55% and is treated as ag-
gressive CLL. It occurs rarely in <1% of cases.
Richter syndrome
Richter syndrome is CLL transformation to ag-
gressive lymphoma, usually DLBCL or Hodgkin like. 
LN biopsy is mandatory for diagnosis, PET may be 
helpful. It occurs in 2%-7% of patients. While novel 
agents are under investigation, CIT is still the recom-
mended approach. Depending on the histologic sub-
type of lymphomatous transformation, patients who 
are suitable for intensive therapy should receive regi-
mens currently employed for either primary diff use 
large B cell lymphoma (Richter syndrome) or Hodg-
kin’s lymphoma. Younger patients who achieve good 
response are candidates for allogeneic stem cell trans-
plantation.
Check point inhibitor pembrolizumab showed ac-
tivity in RS, but not in CLL136-138.
Myelodysplastic syndrome and acute leukemia
Although MDS and AML are uncommon in CLL, 
the rate of therapy related to fl uadarabine based CIT is 
about 5% and much higher after autologous stem cell 
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Table 8. Supportive therapy in patients with B-CLL
PROBLEM RECOMMENDATIONS
1 Vaccination
•  Annual vaccination against infl uenza. Care must be taken of the fact that the recovery 
of B-cell system after anti CD20 antibody therapy lasts for about 9 months, so that 
the response to vaccination in this period is inadequate.
•  Pneumococcal vaccine every 5 years
•  Avoid all live vaccines, including Zoster
2 Anti-infective prophylaxis
•  For patients receiving purine analogs and/or alemtuzumab, and in period after that 
the following prophylaxis is recommended:
 Herpes viruses (acyclovir)
 PCP (sulfamethoxazole/trimethoprim)
•  Special attention in patients receiving alemtuzumab should be paid to the problem 
of CMV reactivation. Although there is no common position in the literature, most 
reports recommend that prophylactic ganciclovir is prescribed if viremia present. 
Th e viral load levels must be monitored every few weeks.
•  For patients receiving anti CD20 antibody and BRI and positive for HBV, HCV 
consult GE/infectologist for antiviral prophylaxis.
3
Respiratory 
infections requiring 
IV antibiotics and 
hospitalization
•  Apply appropriate antibiotic therapy.
•  Determine serum IgG, and if the value is less than 5 g/L:
 Apply monthly IVIG 0.3-0.5 g/kg
 Adjust the dose so that the value is maintained above 5 g/L
4
Immunoglobulin 
replacement 
therapy
•  Should be considered as a means of reducing the incidence of bacterial infections 
in patients with a low serum IgG level who have experienced previous major or 
recurrent minor bacterial infections despite optimal antibacterial prophylaxis.
•  Th e goal should be to reduce the incidence of infection and the immunoglobulin dose 
should be adjusted accordingly.
•  Patients should be reviewed regularly to evaluate the eff ectiveness of immunoglobulin 
replacement therapy and whether there is a continuing need for treatment.
•  Patients who develop serious and/or recurrent infections despite antimicrobial 
prophylaxis and immunoglobulin replacement should be managed in conjunction 
with a microbiologist, infectious disease specialist, and/or immunologist. 
5 Blood transfusion
•  Th e use of irradiated blood products should be considered in the following situations: 
indefi nitely in patients treated with a purine analog, following bendamustine until 
more evidence emerges about the risk of transfusion-associated graft versus host 
disease, following alemtuzumab and for 3 months post conditioning with 
chemotherapy or immunotherapy (6 months after total body irradiation) for patients 
undergoing autologous transplantation.
6 Tumor lysis •  Venetoclax can cause severe tumor lysis syndrome. Special precautions and ramp-up therapy should be followed strictly.
transplantation. Th e response to therapy is poor. 
Whether novel agents that do not induce genotoxic 
stress to stem cells reduce the incidence of this serious 
complication is currently under evaluation.
Supportive therapy
Supportive therapy plays an important role in 
management and is carried out in accordance with the 
generally accepted good clinical practice16,17.
Table 8 shows the basic characteristics of support-
ive therapy in B-CLL. Th is covers the area of vaccina-
tion, anti-infective prophylaxis, respiratory recurrent 
infections requiring IV antibiotics and hospitalization, 
immunoglobulin replacement therapy, blood transfu-
sions, and tumor lysis.
Extended version and updates can be found on 
KROHEM website: http://www.krohem.hr/Docu-
ments/AMENDMENT%20KROHEM%20CLL%
20GUIDELINES%20v1.%202016%20%20ENGL.pdf
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Sažetak
SMJERNICE ZA DIJAGNOSTIKU I LIJEČENJE KRONIČNE LIMFOCITNE LEUKEMIJE 
– KROHEM B-CLL 2017.
B. Jakšić, V. Pejša, S. Ostojić-Kolonić, I. Kardum-Skelin, S. Bašić-Kinda, B. Coha, V. Gverić-Krečak, R. Vrhovac, 
O. Jakšić, I. Aurer, J. Sinčić-Petričević, A. Načinović-Duletić i D. Nemet, za Radnu skupinu KROHEM CLL
Nedavni događaji u dijagnostici i liječenju kronične limfocitne leukemije (B-KLL) doveli su do promjene pristupa u 
kliničkoj praksi. Nova liječenja su odobrena na temelju rezultata randomiziranih multicentričnih pokusa za prvu liniju tera-
pije i za liječenje relapsa/refraktorne bolesti, a rezultati brojnih kliničkih pokusa u tijeku trajno doprinose daljnjem unaprje-
đenju terapijskih strategija. Uz to prisutan je bitan porast razumijevanja genskih promjena bolesti zbog velikog napretka 
tehnologije nove generacije sekvencioniranja. Defi niramo trenutni stav Hrvatske suradne skupine za hematološke bolesti o 
dijagnostici i liječenju B-KLL u sadašnjoj tranziciji iz kemo-imunoterapijske paradigme u novu koja se temelji na novoj 
 dijagnostičkoj slojevitosti i izvrsnim terapijskim rezultatima inhibitora B-staničnih receptora (BRI) i Bcl-2 antagonista. To 
se područje brzo razvija kako velik broj kliničkih ispitivanja koja su u tijeku neprestance doprinosi i pruža nova znanja. 
 Vjerujemo da će istraživanje novih terapija uz genomsku dijagnostiku pružiti nove mogućnosti koje će na kraju dovesti do 
vremenski ograničenog liječenja bez kemoterapije i do učinkovitije kliničke skrbi B-KLL na temelju individualizirane i 
 precizne medicine.
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